Skip to main content
. 2019 Oct 3;158(4):304–313. doi: 10.1111/imm.13116

Figure 2.

Figure 2

FOXO3a is a component of the CIITA‐centred MHC II enhanceosome. (a) RAW cells were treated with interferon‐γ (IFN‐γ) and harvested at the indicated time‐points. ChIP assay was performed with anti‐FOXO3a or IgG. (b) HEK293 cells were transfected with indicated expression constructs. Immunoprecipitation was performed with anti‐GFP. (c) RAW cells were treated with IFN‐γ for 12 hr. Re‐ChIP assay was performed with the indicated antibodies. (d, e) RAW cells were transfected with small interfering RNA (siRNA) targeting RFX5 or scrambled siRNA (SCR) followed by treatment with IFN‐γ for 12 hr. Knockdown efficiency was examined by Western blotting. ChIP assay was performed with anti‐FOXO3a. (f) RAW cells were transfected with siRNA targeting FOXO3a or SCR followed by treatment with IFN‐γ for 12 hr. Re‐ChIP assay was performed with the indicated antibodies. Data represent averages of three independent experiments and error bars represent SEM. *P ≤ 0·05.